Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Altus signs $25mm deal with Cystic Fibrosis Foundation; ends

Executive Summary

The Cystic Fibrosis Foundation Therapeutics Inc.--the technology transfer arm of the Cystic Fibrosis Foundation--is paying Altus Biologics (protein-based therapeutics, diagnostics, and industrial products) up to $25mm in development milestones and providing the company with access to its clinical research network, so that Altus may conclude the development of its TheraCLEC-Total pancreatic insufficiency drug.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies